Cytek Biosciences Inc
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies usin… Read more
Cytek Biosciences Inc (CTKB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.002x
Based on the latest financial reports, Cytek Biosciences Inc (CTKB) has a cash flow conversion efficiency ratio of -0.002x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-771.00K) by net assets ($341.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cytek Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Cytek Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cytek Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cytek Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Citic Guoan Wine Co Ltd
SHG:600084
|
0.005x |
|
STCube Inc
KQ:052020
|
-0.064x |
|
Zhejiang Yueling Co Ltd
SHE:002725
|
0.008x |
|
Solareast Holdings Co Ltd
SHG:603366
|
0.015x |
|
Comture Corporation
PINK:CMTUF
|
0.017x |
|
Nuh Cimento Sanayi AS
IS:NUHCM
|
0.012x |
|
Ningxia Building Materials Group Co Ltd
SHG:600449
|
0.040x |
|
Sichuan Fulin Transportation Group Co Ltd
SHE:002357
|
0.006x |
Annual Cash Flow Conversion Efficiency for Cytek Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Cytek Biosciences Inc from 2019 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $341.74 Million | $-4.69 Million | -0.014x | -121.38% |
| 2024-12-31 | $395.74 Million | $25.38 Million | 0.064x | +377.33% |
| 2023-12-31 | $393.06 Million | $5.28 Million | 0.013x | +146.75% |
| 2022-12-31 | $425.55 Million | $-12.23 Million | -0.029x | -351.65% |
| 2021-12-31 | $405.38 Million | $4.63 Million | 0.011x | +101.21% |
| 2020-12-31 | $-16.03 Million | $15.16 Million | -0.946x | -386.84% |
| 2019-12-31 | $-41.70 Million | $-13.75 Million | 0.330x | -- |